Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 04, 2007. The report details a specific corporate action regarding the repurchase and cancellation of the Company's ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 2,570,000 ordinary shares of 25 pence each.
- Purchase Price: 1,291.1384 pence per share.
- Treasury Shares Held: 504,194,158 shares (representing 9.14% of total voting rights).
- Shares in Issue: 5,516,866,846 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the Company's share capital through the cancellation of 2,570,000 shares. Consequently, the number of shares held in Treasury has been updated to 504,194,158. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It strictly serves as a notification of the share repurchase and the resulting capital structure. The document explicitly states it does not constitute an offer or solicitation to purchase securities.
Key Facts for Investor Verification
- Verify the total cost of the buyback by multiplying 2,570,000 shares by the price of 1,291.1384 pence.
- Confirm the updated total voting rights denominator of 5,516,866,846 shares for compliance with Disclosure Transparency Rules.
- Note that 9.14% of voting rights are currently held in Treasury and are excluded from the shares in issue.
- Recognize that this filing does not contain quarterly or annual financial performance results.